Abstract

Purpose This systematic review and meta-analysis were performed to assess the efficacy and tolerability of chemotherapy in patients with advanced gastric cancer. Methods Randomized phase II and III clinical trials on first-line chemotherapy in advanced gastric cancer were identified by electronic searches of Medline, Embase, the Cochrane Controlled Trials Register, and Cancerlit; hand searches of relevant abstract books and reference lists; and contact to experts. Meta-analysis was performed using the fixed-effect model. Overall survival, reported as hazard ratio (HR) with 95% CI, was the primary outcome measure. Results Analysis of chemotherapy versus best supportive care (HR = 0.39; 95% CI, 0.28 to 0.52) and combination versus single agent, mainly fluorouracil (FU) -based chemotherapy (HR = 0.83; 95% CI = 0.74 to 0.93) showed significant overall survival benefits in favor of chemotherapy and combination chemotherapy, respectively. In addition, comparisons of FU/cisplatin-containing regimens with versus without anthracyclines (HR = 0.77; 95% CI, 0.62 to 0.95) and FU/anthracycline-containing combinations with versus without cisplatin (HR = 0.83; 95% CI, 0.76 to 0.91) both demonstrated a significant survival benefit for the three-drug combination. Comparing irinotecan-containing versus nonirinotecan-containing combinations (mainly FU/cisplatin) resulted in a nonsignificant survival benefit in favor of the irinotecan-containing regimens (HR = 0.88; 95% CI, 0.73 to 1.06), but they have never been compared against a three-drug combination. Conclusion Best survival results are achieved with three-drug regimens containing FU, an anthracycline, and cisplatin. Among these, regimens including FU as bolus exhibit a higher rate of toxic deaths than regimens using a continuous infusion of FU, such as epirubicin, cisplatin, and continuous-infusion FU.

Keywords

MedicineIrinotecanInternal medicineCochrane LibraryTolerabilityMeta-analysisChemotherapyOncologyHazard ratioCisplatinAnthracyclineCombination chemotherapyRandomized controlled trialCancerConfidence intervalColorectal cancerAdverse effectBreast cancer

Affiliated Institutions

Related Publications

Publication Info

Year
2006
Type
review
Volume
24
Issue
18
Pages
2903-2909
Citations
1179
Access
Closed

External Links

Social Impact

Social media, news, blog, policy document mentions

Citation Metrics

1179
OpenAlex

Cite This

Dorothea Wagner, Wilfried Grothe, Johannes Haerting et al. (2006). Chemotherapy in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis Based on Aggregate Data. Journal of Clinical Oncology , 24 (18) , 2903-2909. https://doi.org/10.1200/jco.2005.05.0245

Identifiers

DOI
10.1200/jco.2005.05.0245